Metabolomics Monitoring of Treatment Response to Brain Tumor Immunotherapy

被引:15
作者
Dastmalchi, Farhad [1 ]
Deleyrolle, Loic P. [1 ]
Karachi, Aida [1 ]
Mitchell, Duane A. [1 ]
Rahman, Maryam [1 ]
机构
[1] Univ Florida, Dept Neurosurg, Preston A Wells Jr Ctr Brain Tumor Therapy, Gainesville, FL 32611 USA
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
关键词
metabolic signature; metabolomics monitoring; biomarker; cancer; brain tumor; immunotherapy; T-CELL-ACTIVATION; MACROPHAGE ACTIVATION; SUPPRESSOR-CELLS; DENDRITIC CELLS; PLASMA SAMPLES; CANCER; METABOLISM; SURVIVAL; GLIOBLASTOMA; BLOOD;
D O I
10.3389/fonc.2021.691246
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immunotherapy has revolutionized care for many solid tissue malignancies, and is being investigated for efficacy in the treatment of malignant brain tumors. Identifying a non-invasive monitoring technique such as metabolomics monitoring to predict patient response to immunotherapy has the potential to simplify treatment decision-making and to ensure therapy is tailored based on early patient response. Metabolomic analysis of peripheral immune response is feasible due to large metabolic shifts that immune cells undergo when activated. The utility of this approach is under investigation. In this review, we discuss the metabolic changes induced during activation of an immune response, and the role of metabolic profiling to monitor immune responses in the context of immunotherapy for malignant brain tumors. This review provides original insights into how metabolomics monitoring could have an important impact in the field of tumor immunotherapy if achievable.
引用
收藏
页数:13
相关论文
共 102 条
  • [71] Myeloid C-type Lectin Receptors in Pathogen Recognition and Host Defense
    Osorio, Fabiola
    Reis e Sousa, Gaetano
    [J]. IMMUNITY, 2011, 34 (05) : 651 - 664
  • [72] Metabolomic signature of brain cancer
    Pandey, Renu
    Caflisch, Laura
    Lodi, Alessia
    Brenner, Andrew J.
    Tiziani, Stefano
    [J]. MOLECULAR CARCINOGENESIS, 2017, 56 (11) : 2355 - 2371
  • [73] Warburg metabolism in tumor-conditioned macrophages promotes metastasis in human pancreatic ductal adenocarcinoma
    Penny, Hweixian Leong
    Sieow, Je Lin
    Adriani, Giulia
    Yeap, Wei Hseun
    Ee, Peter See Chi
    San Luis, Boris
    Lee, Bernett
    Lee, Terence
    Mak, Shi Ya
    Ho, Ying Swan
    Lam, Kong Peng
    Ong, Choon Kiat
    Huang, Ruby Y. J.
    Ginhoux, Florent
    Rotzschke, Olaf
    Kamm, Roger D.
    Wong, Siew Cheng
    [J]. ONCOIMMUNOLOGY, 2016, 5 (08):
  • [74] Methods to measure T-cell responses
    Plebanski, Magdalena
    Katsara, Maria
    Sheng, Kuo-ching
    Xiang, Sue Dong
    Apostolopoulos, Vasso
    [J]. EXPERT REVIEW OF VACCINES, 2010, 9 (06) : 595 - 600
  • [75] Differential control of cell cycle, proliferation, and survival of primary T lymphocytes by purine and pyrimidine nucleotides
    Quéméneur, L
    Gerland, LM
    Flacher, M
    Ffrench, M
    Revillard, JP
    Genestier, L
    [J]. JOURNAL OF IMMUNOLOGY, 2003, 170 (10) : 4986 - 4995
  • [76] Quinn KM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16633-7
  • [77] (R)-2-hydroxyglutarate drives immune quiescence in the tumor microenvironment of IDH-mutant gliomas
    Richardson, Leland G.
    Choi, Bryan D.
    Curry, William T.
    [J]. TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S167 - S170
  • [78] Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
    Royal, Richard E.
    Levy, Catherine
    Turner, Keli
    Mathur, Aarti
    Hughes, Marybeth
    Kammula, Udai S.
    Sherry, Richard M.
    Topalian, Suzanne L.
    Yang, James C.
    Lowy, Israel
    Rosenberg, Steven A.
    [J]. JOURNAL OF IMMUNOTHERAPY, 2010, 33 (08) : 828 - 833
  • [79] Salgaller ML, 1998, PROSTATE, V35, P144, DOI 10.1002/(SICI)1097-0045(19980501)35:2<144::AID-PROS8>3.0.CO
  • [80] 2-J